TUMOUR HYPERPROGRESSION

This adverse event was reported 248 times

These drugs are most commonly taken by patients reporting TUMOUR HYPERPROGRESSION:

# Drug Count
0 DURVALUMAB 36
1 NIVOLUMAB 27
2 CARBOPLATIN 26
3 PACLITAXEL 19
4 BEVACIZUMAB 14
5 PEMETREXED DISODIUM 14
6 IPILIMUMAB 13
7 TREMELIMUMAB 13
8 ETOPOSIDE 11
9 LANSOPRAZOLE 8
See all common drugs associated with TUMOUR HYPERPROGRESSION

TUMOUR HYPERPROGRESSION is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 NIVOLUMAB AND RELATLIMAB-RMBW 2 0.0039
1 TREMELIMUMAB 13 0.0029
2 DURVALUMAB 36 0.0017
3 CEMIPLIMAB-RWLC 3 0.0014
4 MEPIVACAINE HYDROCHLORIDE 1 0.0009
5 ENFORTUMAB VEDOTIN 6 0.0008
6 TALIMOGENE LAHERPAREPVEC 1 0.0006
7 SOTORASIB 2 0.0006
8 AMPICILLIN SODIUM AND SULBACTAM SODIUM 1 0.0004
9 PEMETREXED DISODIUM 14 0.0004
See all drugs enriched for association with TUMOUR HYPERPROGRESSION